Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients
Open Access
- 1 September 2006
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (9) , 3329-3336
Abstract
Context: Mutations in transcription factors result in combined pituitary hormone deficiency (CPHD). Objective: A genetic screening strategy, based on endocrine and neuroradiological phenotype according to published knowledge, was applied to establish the prevalence of gene defects in each category of patients and provide a useful framework for clinicians to determine the genetic etiology and recurrence risks for individuals and families. Design: One hundred ninety-five CPHD patients from the international GENHYPOPIT network were studied, according to their phenotype, for POU1F1, PROP1, LHX3, LHX4, and HESX1. Patients: Patients selected had two pituitary hormone deficiencies or at least one deficiency with intracerebral malformations. Results: Total prevalence of mutations was 13.3 and 52.4% in 20 patients with familial CPHD history. No mutation of HESX1 was observed in 16 patients harboring septooptic dysplasia. A mutation of LHX4 gene, previously reported, was found in one familial case from 39 patients bearing pituitary stalk interruption syndrome. In 109 patients without extrapituitary abnormalities, 20 had PROP1 mutations, including eight patients with a family history of CPHD. Among 20 patients without pituitary stalk interruption syndrome, no LHX3 gene defect was found, even with a neck rotation deficit. One POU1F1 gene defect was found in one patient presenting the rare postpubertal association of thyrotroph (TSH deficiency) and somatotroph (GH deficiency) deficits. Conclusions: Mutation of PROP1 gene remains the first to be looked for, and POU1F1 mutations should be sought in GH deficiency and TSH deficiency postpubertal population without extrapituitary malformations. Identification of gene defects allows early treatment of any deficit and prevention of their potentially fatal consequences. Genotyping appears highly beneficial at an individual and familial level.Keywords
This publication has 31 references indexed in Scilit:
- Novel Mutations within the POU1F1 Gene Associated with Variable Combined Pituitary Hormone DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 2005
- Mutation analysis of POUF‐1, PROP‐1 and HESX‐1 show low frequency of mutations in children with sporadic forms of combined pituitary hormone deficiency and septo‐optic dysplasiaClinical Endocrinology, 2005
- PROP1 Gene Screening in Patients with Multiple Pituitary Hormone Deficiency Reveals Two Sites of Hypermutability and a High Incidence of Corticotroph DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 2001
- Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 geneEuropean Journal of Endocrinology, 2000
- Familial growth hormone deficiency associated with MRI abnormalitiesAmerican Journal of Medical Genetics, 1998
- Rarity of PIT1 involvement in children from Russia with combined pituitary hormone deficiencyAmerican Journal of Medical Genetics, 1998
- Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfismNature, 1996
- Mutation of the POU-Specific Domain of Pit-1 and Hypopituitarism Without Pituitary HypoplasiaScience, 1992
- A Mutation in the POU-Homeodomain of Pit-1 Responsible for Combined Pituitary Hormone DeficiencyScience, 1992
- Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1Nature, 1990